Article

Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.

Department of Surgery, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Diseases of the Esophagus (Impact Factor: 2.06). 02/2008; 21(2):151-8. DOI: 10.1111/j.1442-2050.2007.00732.x
Source: PubMed

ABSTRACT Our aim was to determine if fluorodeoxyglucose positron emission tomography (FDG-PET) could be correlated with a pathological response in patients with esophageal adenocarcinoma receiving neoadjuvant chemotherapy and/or chemoradiation therapy. Patients with resectable, histologically proven adenocarcinoma of the esophagus were entered in the study. Preoperative chemotherapy comprised two cycles of cisplatin and 5-fluorouracil. Radiation therapy commenced with the second cycle on day 22. FDG-PET images were obtained pre-treatment and on completion of intended neo-adjuvant treatment. Quantification was achieved by the calculation of both standardized uptake values (SUV) and tumor/liver ratios (TLR). Evidence of histopathological response was identified according to the Mandard tumor regression scoring system. There were 45 patients, 22 receiving neoadjuvant chemotherapy and 23 chemoradiation therapy. Forty patients underwent surgical resection. Seven patients (16%) had a histopathological response. The mean percentage change in SUV in the histological responders group was -56.8% (SD 29) and in the non-responders -27.8% (SD 32.1) (P = 0.035). The mean percentage change in TLR was -49.1% (SD 44.8) in the responders and in the non-responders -27.3% (SD 31.3) (P = 0.128). There was no difference between the two methods of assessment, however there was less variation with SUV. There was no correlation between the FDG-PET response and the histopathological response. Presently an FDG-PET scan performed 3-6 weeks after neoadjuvant therapy for adenocarcinoma of the esophagus should not be used as a marker of the potential result of the treatment. The optimal timing of a second FDG-PET remains unclear.

0 Bookmarks
 · 
84 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neben ihrem Stellenwert im initialen Staging (v. a. zum Ausschluss einer Fernmetastasierung) und in der Rezidivdiagnostik des Ösophaguskarzinoms kann die Positronenemissionstomographie mit Fluordesoxyglucose (FDG-PET) auch zur Kontrolle des Therapieansprechens verwendet werden. Eine neoadjuvante Chemo-/Radiochemotherapie kann das Überleben von Patienten mit Ösophaguskarzinom signifikant verbessern, doch profitieren davon nur Patienten mit Ansprechen auf die Induktionstherapie. Die Kontrolle des Therapieansprechens kann spät, d. h. nach Ende der neoadjuvanten Therapie, sowie früh im Therapieverlauf erfolgen. Als Surrogatparameter zur Vorhersage des Therapieansprechens und der Prognose für Adenokarzinome des gastroösophagealen Übergangs wurde die FDG-PET bereits in mehreren Studien evaluiert und validiert. Die unizentrische MUNICON-Studie zeigte, dass eine PET/CT-gesteuerte Therapie beim Adenokarzinom des Ösophagus möglich ist, was hinsichtlich einer Individualisierung der multimodalen Therapie wichtig ist. In anderen Studien war die FDG-PET hinsichtlich Ansprechen und Prognose jedoch nicht aussagekräftig. Die Rolle der FDG-PET/CT in der Therapiekontrolle des Ösophaguskarzinoms wird intensiv diskutiert. Prospektive randomisierte multizentrische Studien sind noch erforderlich. Außerhalb von Studien sollte die PET/CT-gesteuerte Therapie nicht eingesetzt werden. Zukünftige Forschung wird sich auch neuen Möglichkeiten der molekularen Bildgebung sowie innovativen Therapieregimes widmen.
    Der Onkologe 01/2010; 16(5). DOI:10.1007/s00761-010-1832-8 · 0.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Functional imaging gives information about physiological heterogeneity in tumours. The utility of functional imaging tests in providing predictive and prognostic information after chemoradiotherapy for both oesophageal cancer and pancreatic cancer will be reviewed. The benefit of incorporating functional imaging into radiotherapy planning is also evaluated. In cancers of the upper gastrointestinal tract, the vast majority of functional imaging studies have used (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET). Few studies in locally advanced pancreatic cancer have investigated the utility of functional imaging in risk-stratifying patients or aiding target volume definition. Certain themes from the oesophageal data emerge, including the need for a multiparametric assessment of functional images and the added value of response assessment rather than relying on single time point measures. The sensitivity and specificity of FDG-PET to predict treatment response and survival are not currently high enough to inform treatment decisions. This suggests that a multimodal, multiparametric approach may be required. FDG-PET improves target volume definition in oesophageal cancer by improving the accuracy of tumour length definition and by improving the nodal staging of patients. The ideal functional imaging test would accurately identify patients who are unlikely to achieve a pathological complete response after chemoradiotherapy and would aid the delineation of a biological target volume that could be used for treatment intensification. The current limitations of published studies prevent integrating imaging-derived parameters into decision making on an individual patient basis. These limitations should inform future trial design in oesophageal and pancreatic cancers.
    Clinical Oncology 07/2014; 26(9). DOI:10.1016/j.clon.2014.06.009 · 2.83 Impact Factor
    This article is viewable in ResearchGate's enriched format
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the relationship between hematologic test results and the predictive effect of regression of esophageal cancer after neoadjuvant chemotherapy (NACT), we analyzed pre-NACT hematologic data and their relationship to tumor regression. Thirty-eight consecutive patients with locally advanced squamous cell esophageal carcinoma who had undergone two cycles of paclitaxel/carboplatin NACT were enrolled. On the day prior to the first cycle of chemotherapy, hematologic tests, including routine blood test and biochemical examinations, were recorded. All patients were confirmed to have no history of hepatitis. Surgical resection was performed when clinical restaging showed effective regression. Histopathological examination was routinely performed to evaluate the postoperative effects of chemotherapy. After two cycles of NACT, tumor imaging evaluation showed that 27 of the 38 patients had CR and PR, including 25 patients who underwent radical esophagectomies. Six patients had stable disease and five patients had progressive disease. According to the hematologic test results before NACT, patients with higher white blood cell counts, lymphocyte percentages, mononuclear cell counts, neutrophilic granulocyte counts, and eosinophilic granulocyte counts and lower alanine aminotransferase (ALT) level had a significantly greater opportunity for an effective response. Basal host immunologic function and hepatic function are associated with tumor response to NACT in patients with esophageal cancer. These parameters may have a certain predictive efficacy on NACT for esophageal squamous cell carcinoma.
    World Journal of Surgical Oncology 02/2014; 12(1):43. DOI:10.1186/1477-7819-12-43 · 1.20 Impact Factor
    This article is viewable in ResearchGate's enriched format

Full-text (2 Sources)

Download
38 Downloads
Available from
May 20, 2014